Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES --(BUSINESS WIRE)--May 7, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026.
LOS ANGELES --(BUSINESS WIRE)--May 6, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma
LOS ANGELES --(BUSINESS WIRE)--Apr. 23, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results.
LOS ANGELES --(BUSINESS WIRE)--Apr. 2, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma